<div id="readability-page-1"><p>Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) have been given a consensus rating of &#34;Buy&#34; by the eleven ratings firms that are currently  covering the company, Marketbeat.com reports. One equities research analyst  has rated the stock with a sell recommendation, seven have issued  a buy recommendation and three have assigned  a strong buy recommendation to  the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $53.8750.</p><div><p><span></span><span>Get <strong>Spyre Therapeutics</strong> alerts:</span></p></div><p>A number of research firms have recently commented on SYRE. Mizuho upgraded shares of Spyre Therapeutics to a &#34;strong-buy&#34; rating in a report on Thursday, December 18th. Weiss Ratings  reissued a &#34;sell (e+)&#34; rating on shares of Spyre Therapeutics in a research report on Monday, December 29th. Jones Trading raised shares of Spyre Therapeutics from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $64.00 target price on the stock in a research report on Monday, December 1st. BTIG Research  reiterated a &#34;buy&#34; rating and issued a $70.00 price target on shares of Spyre Therapeutics in a report on Tuesday, September 16th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Spyre Therapeutics in a research note on Friday, September 26th. They issued a &#34;buy&#34; rating and a $43.00 price objective on the stock.</p><p><b>View Our Latest Stock Analysis on SYRE</b></p><h2>Spyre Therapeutics Stock Performance</h2><p>Shares of NASDAQ SYRE opened at $31.05 on Thursday. Spyre Therapeutics has a fifty-two week low of $10.91 and a fifty-two week high of $35.31. The company has a market cap of $2.41 billion, a price-to-earnings ratio of -14.18 and a beta of 3.17. The business's 50 day moving average price is $29.13 and its 200-day moving average price is $21.39. </p><p>Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.68) by $0.53.  Sell-side analysts predict that  Spyre Therapeutics will post -4.46 earnings per share for the current year. </p><h2>Insider Activity at Spyre Therapeutics</h2><p>In related news, CEO Cameron Turtle sold 45,000 shares of Spyre Therapeutics stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $23.33, for a total value of $1,049,850.00. Following the completion of the sale, the chief executive officer directly owned 701,907 shares in the company, valued at $16,375,490.31. The trade was a 6.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold a total of 75,000 shares of company stock worth $1,945,350 in the last 90 days. Company insiders own  15.43% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its position in shares of  Spyre Therapeutics by 8.4% in the 3rd quarter. Wellington Management Group LLP now owns 1,640,312 shares of the company's stock worth $27,492,000 after purchasing an additional 126,834 shares during the period.  Jefferies Financial Group Inc. raised its stake in  Spyre Therapeutics by 11.2% in the second quarter. Jefferies Financial Group Inc. now owns 1,388,854 shares of the company's stock worth $20,791,000 after buying an additional 140,000 shares in the last quarter.  Geode Capital Management LLC raised its stake in  Spyre Therapeutics by 15.8% in the second quarter. Geode Capital Management LLC now owns 1,227,232 shares of the company's stock worth $18,373,000 after buying an additional 167,669 shares in the last quarter.  TCG Crossover Management LLC purchased a new stake in  Spyre Therapeutics during the third quarter worth $18,446,000.  Finally, Baker BROS. Advisors LP boosted its position in  Spyre Therapeutics by 59.6% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,000,000 shares of the company's stock valued at $16,760,000 after acquiring an additional 373,297 shares in the last quarter. Hedge funds and other institutional investors own  80.39% of the company's stock. </p><h2>About Spyre Therapeutics</h2> (Get Free Report)<p>Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.  </p><p>Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.</p><h2>See Also</h2><ul><li>Five stocks we like better than Spyre Therapeutics</li><li>You Still Think Silver’s a Joke? Watch What Happens Next.</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>A month before the crash</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>YDES Could Be 2026's Biotech Breakthrough</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1lSRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1lSRQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Spyre Therapeutics Right Now?</h2><p>Before you consider Spyre Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.</p><p>While Spyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SYRE

<p>Spyre Therapeutics, Inc. (NASDAQ:SYRE) has received a consensus rating of "Buy" from eleven brokerages, with one sell, seven buy, and three strong buy recommendations. The average 12-month target price is $53.88. Recent ratings include a strong buy from Mizuho and a buy from Jones Trading with a target of $64.00. The stock opened at $31.05, with a 52-week range of $10.91 to $35.31. CEO Cameron Turtle sold 45,000 shares recently, reducing ownership to 701,907 shares. Institutional investors hold 80.39% of the stock.</p>

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Brokerages